Regulatoriskt pressmeddelande

The first tranche of the directed share issue completed

Senzime AB (publ) (“Senzime” or the “Company”) announced on June 2, 2025 the board of directors’ resolution to carry out a directed share issue of up to 24,000,000 shares at the subscription price SEK 4.60 per share (the ”Share Issue”). In the first tranche of the Share Issue (23,300,000 shares) 22,250,000 shares has now been subscribed, allocated and transferred. As a result, the Company will receive MSEK 102.38 (before issue costs). This leaves approximately MSEK 4.8, which will preliminarily be paid around June 24, 2025. When this payment has been made, all shares in the first tranche will be subscribed, allotted and transferred.

As previously communicated, the Share Issue will be carried out in two separate tranches. The first tranche (“Tranche 1”) comprises 23,300,000 shares – which, with the subscription price mentioned above, correspond to approximately MSEK 107.18 - and is issued by the board of directors based on the authorization received at the annual general meeting on 19 May 2025. The persons entitled to subscribe for Tranche 1 were a limited number of investors who expressed a long-term commitment to the Company, including a group of new institutional investors including Unionen (Sweden’s largest trade union), Protean and ShapeQ Gmbh, as well as existing and long-term investors including the Crafoord family and Foundation, Segulah Medical Acceleration, Fredrik Rapp and Swedbank Robur.

The second tranche (“Tranche 2”) consists of a maximum of 700,000 shares – which, with the subscription price mentioned above, correspond to approximately MSEK 3.22 – and was resolved by the board of directors, subject to approval by an extraordinary general meeting of the Company. Notice of the extraordinary general meeting, to be held on June 30, 2025, has been published in a separate press release. The person entitled to subscribe for the shares in Tranche 2 is the board member Adam Dahlberg.

A total of 22,250,000 shares in Tranche 1 has now been subscribed, allotted, transferred to the investors. The remaining 1,050,000 shares in Tranche 1 are expected to be paid on or around June 24, 2025. Once that payment has been made, all shares in Tranche 1 will be subscribed, allotted and transferred. Following the completion of Tranche 1 as described above, the number of shares in the Company will have increased by 23,300,000, from 133,215,046 to 156,515,046. The Company’s share capital will have increased by SEK 2,912,500, from SEK 16,651,880.75 to SEK 19,564,380.75. Tranche 1 entails a dilution of approximately 14.9 percent based on the total number of shares in the Company after Tranche 1.

Advisers
Zonda Partners has acted as financial advisor in connection with the Share Issue and Advokatfirman Lindahl has acted as legal advisor.

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.